MabVax Therapeutics Holdings is a clinical-stage biopharmaceutical company with a focus on the discovery, development and commercialization of proprietary human monoclonal antibody products and vaccines for the diagnosis and treatment of certain cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. For more information, visit the company’s website at www.mabvax.com